CMC(SH:603122) Mei Ri Jing Ji Xin Wen·2025-11-15 02:46Core Viewpoint - The stock of HeFu China (SH603122) has experienced significant volatility, with a cumulative increase of 256.29% over 14 trading days, leading to a temporary suspension of trading to protect investors' interests [1][5]. Trading Performance - HeFu China achieved 12 out of 14 trading days with a closing price at the daily limit, with a total trading volume of 8.859 million hands and a total transaction value of 13.48 billion yuan, resulting in a turnover rate of 222.56% [5]. - During the same period, the relevant sector's performance was only a 14.11% increase, while the overall market index saw a decline of 0.16% [5]. Financial Performance - In Q3 2025, HeFu China reported a net profit attributable to shareholders of approximately -5.05 million yuan, a year-on-year decline of 225.26%, primarily due to changes in the domestic macroeconomic environment and price reductions in the medical industry [12]. - The company's revenue for the reporting period was 181.2 million yuan, down 21.27% year-on-year, and the total profit was -5.44 million yuan, a decrease of 193.80% [14]. Market Valuation - As of November 14, 2025, HeFu China's static price-to-earnings (P/E) ratio was 343.67, significantly higher than the industry average of 30.94, indicating a potential overvaluation of the stock [14]. - The company has warned that its stock price has deviated significantly from its fundamentals, suggesting that investors may face considerable risks if the stock continues to rise abnormally [11][15]. Company Background - HeFu China, established in October 2000 and listed on the Shanghai Stock Exchange in February 2022, has built long-term cooperative relationships with over 1,000 domestic and international manufacturers and agents [15]. - The company provides a wide range of in vitro diagnostic products and consumables, with nearly 37,000 items offered to hospitals as of mid-2025 [15].